Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: June 30, 2006
Last updated: June 30, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)